Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Arthur

Neurological Surgery Memphis, TN Medical Doctor

NPI 1982693313 CMS profile 90355

6325 Humphreys Blvd, Memphis, TN 38120

Open in the dashboard

General payments

$1,879,849

781 records reported · program years 2019–2025

Research payments

$114,462

Paid to them · 16 records reported · program years 2019–2025

Ownership & investment interest

$1,814,921

7 holdings reported · through program year 2025

Research they led as principal investigator

$3,470,267 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Adam Arthur of Memphis, TN is reported in the CMS Open Payments database as having received $1,879,849 across 781 general payments and $114,462 in research payments paid to them. Separately, studies naming them as principal investigator received $3,470,267 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $1,814,921 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

15 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $369,279 111
2024 General $172,933 100
2023 General $245,149 92
2022 General $608,603 107
2022 Research $20,250 3
2021 General $131,161 116
2021 Research $40,600 5
2020 General $108,958 86
2020 Research $500 1
2019 General $243,766 169
2019 Research $53,112 7
2025 Ownership $752,104 2
2024 Ownership $747,721 2
2023 Ownership $20,367 1
2021 Ownership $294,730 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Arthur
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Adam Arthur were reported at $369,279. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Adam Arthur Neurological Surgery median Middle half National median
2019 $243,766 $582 $138–$3,006 $163
2020 $108,958 $294 $76–$2,174 $114
2021 $131,161 $387 $105–$2,432 $132
2022 $608,603 $542 $139–$2,989 $149
2023 $245,149 $534 $145–$2,697 $160
2024 $172,933 $574 $155–$3,046 $164
2025 $369,279 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. MicroVention, Inc. $593,969 313 payments
  2. Triad Life Sciences Inc. $434,565 4 payments
  3. Scientia Vascular $226,502 8 payments
  4. Stryker Corporation $221,489 146 payments
  5. Penumbra, Inc. $140,091 52 payments
  6. Medtronic, Inc. $77,678 32 payments
  7. Medical Device Business Services, Inc. $69,040 62 payments
  8. Medtronic USA, Inc. $52,038 20 payments
  9. Siemens Medical Solutions USA, Inc. $34,338 46 payments
  10. Imperative Care, INc $9,607 21 payments
  11. Other $20,533 77 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $897,255 172 payments
  2. Acquisitions $502,674 5 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $307,429 100 payments
  4. Travel and Lodging $143,984 168 payments
  5. Food and Beverage $19,784 334 payments
  6. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $8,700 1 payment
  7. Gift $24 1 payment
Products named General payments · program years 2019–2025
  1. WEB ANEURYSM EMBOLIZATION SYSTEM Neurological Product $286,889 97 payments
  2. WEB $182,957 111 payments
  3. SURPASS EVOLVE $110,085 45 payments
  4. Artemis $101,134 23 payments
  5. WEB Aneurysm Embolization System Neurological Product $74,002 42 payments
  6. Aristotle Guidewire $60,358 3 payments
  7. SURPASS $24,504 15 payments
  8. Pipeline $20,406 4 payments
  9. MEDPOR $18,750 1 payment
  10. TRUFILL $18,380 17 payments
  11. Other $235,592 316 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. MicroVention, Inc. $57,262 8 payments
  2. Sequent Medical, Inc. $53,100 6 payments
  3. Balt USA, LLC $3,600 1 payment
  4. Stryker Corporation $500 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

56

Median for Neurosurgery: 83

Drug cost

$449

Median for Neurosurgery: $872

Branded share of claims

100%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 56 $449

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$97,323

Of which drugs: $825

Medicare patients

308

Average age 74

Services billed

3,646

199 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 44%
Diabetes 38%
Depression 29%
Chronic kidney disease 26%
Atrial fibrillation 24%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml A9579 Office 27 505 $597
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 23 2,320 $228

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

797 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record